Surmodics (SRDX)
(Delayed Data from NSDQ)
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.80 USD
+0.02 (0.05%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $41.84 +0.04 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth C Momentum F VGM
Zacks News
Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis
by Zacks Equity Research
PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.
Masimo (MASI) Introduces Automation and Connectivity Solution
by Zacks Equity Research
Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.
Here's Why You Should Retain Merit Medical (MMSI) for Now
by Zacks Equity Research
Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.
VREX vs. SRDX: Which Stock Is the Better Value Option?
by Zacks Equity Research
VREX vs. SRDX: Which Stock Is the Better Value Option?
QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results
by Zacks Equity Research
Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Investor confidence is high on Nevro (NVRO), thanks to solid prospects
BD Unveils BD PurPrep Patient Preoperative Skin Preparation
by Zacks Equity Research
By developing fully sterile PurPrep, BD (BDX) is offering health care experts a more complete set of tools to mitigate the risk of intrinsic contamination in antiseptic solutions.
Here's Why You Should Retain Avanos Medical Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), thanks to solid prospects.
Here's Why You Should Retain DaVita in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA), thanks to solid prospects.
NextGen Virtual Visits Offers Remote Eye Care Facilities
by Zacks Equity Research
The offering will expand NextGen's (NXGN) ophthalmology services during the coronavirus crisis.
LHC Group Inks Deal With Orlando Health to Improve HCBS
by Zacks Equity Research
This deal is expected to boost LHC Group's (LHCG) home and community-based business segment.
Quidel (QDEL) Catches Eye: Stock Jumps 6.3%
by Zacks Equity Research
Quidel (QDEL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Why Surmodics (SRDX) Could Be Positioned for a Surge
by Zacks Equity Research
Surmodics (SRDX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Ecolab's Unit Unveils Test Kit for Cooling Water Management
by Zacks Equity Research
Ecolab's (ECL) bacteria test kit drastically simplifies water-chemistry testing and compliance for cooling water health.
Top Ranked Momentum Stocks to Buy for June 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 29th.
Top Ranked Momentum Stocks to Buy for June 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 26th
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Surmodics (SRDX), thanks to solid prospects.
NextGen Virtual Visits Supports Women Health During COVID-19
by Zacks Equity Research
Capital Women's Care is set to expand NextGen's (NXGN) women's healthcare services during the coronavirus emergency.
Allscripts' (MDRX) Veradigm Partners with PAN Foundation
by Zacks Equity Research
This partnership between Allscripts (MDRX) and PAN Foundation is expected to boost patient outcomes.
Masimo Launches Masimo SafetyNet-Open to Fight Coronavirus
by Zacks Equity Research
Masimo's (MASI) newly-launched SafetyNet-Open has been developed to ensure health and safety during the coronavirus outbreak.
Here's Why You Should Retain Glaukos in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.
ABIOMED Unveils Digital Platform CAMP PCI for CAD Treatment
by Zacks Equity Research
ABIOMED's (ABMD) new digital platform helps to deliver better patient outcomes for those suffering from CAD.
Here's Why You Should Add HMS Holdings to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on HMS Holdings (HMSY) stock, thanks to solid prospects.
Can SurModics (SRDX) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.